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The endothelin receptor type A (EDNRA) signaling pathway is essential for the establishment of mandibular identity during develop-
ment of the first pharyngeal arch. We report four unrelated individuals with the syndrome mandibulofacial dysostosis with alopecia
(MFDA) who have de novo missense variants in EDNRA. Three of the four individuals have the same substitution, p.Tyr129Phe.
Tyr129 is known to determine the selective affinity of EDNRA for endothelin 1 (EDN1), its major physiological ligand, and the p.Tyr129-
Phe variant increases the affinity of the receptor for EDN3, its non-preferred ligand, by two orders of magnitude. The fourth individual
has a somatic mosaic substitution, p.Glu303Lys, and was previously described as having Johnson-McMillin syndrome. The zygomatic
arch of individuals withMFDA resembles that of mice in which EDNRA is ectopically activated in themaxillary prominence, resulting in
a maxillary to mandibular transformation, suggesting that the p.Tyr129Phe variant causes an EDNRA gain of function in the developing
upper jaw. Our in vitro and in vivo assays suggested complex, context-dependent effects of the EDNRA variants on downstream
signaling. Our findings highlight the importance of finely tuned regulation of EDNRA signaling during human craniofacial development
and suggest that modification of endothelin receptor-ligand specificity was a key step in the evolution of vertebrate jaws.Introduction
During early embryonic head development, neural crest
cells (NCCs) migrate from the dorsal neural tube to popu-
late the pharyngeal arches (PAs), where they give rise to the
cartilage and bones of the face. Caudally, NCCs contribute
to the conotruncus of the heart, the peripheral nervous
system, the enteric nervous system, melanocytes, and
para-endocrine cells.1 The endothelin signaling system
(i.e., ligands plus receptors) is a vertebrate-specific innova-
tion2 implicated in the development of several NCC-
derived tissues. In mammals, the system is comprised of
three ligands (encoded by EDN1 [MIM 131240], EDN2
[MIM 131241], and EDN3 [MIM 131242]) and two recep-
tors (encoded by EDNRA [MIM 131243] and EDNRB
[MIM 131244]) belonging to the G protein-coupled seven
transmembrane domain receptor family.3 All three ligands
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The Ambind to EDNRA with an affinity two orders of magnitude
higher than that of EDN3.4,5 The first PA is comprised of
maxillary and mandibular prominences, which give rise
to the upper and lower jaws, respectively. EDN1-EDNRA
signaling plays a critical role in specification of mandibular
identity in post-migratory NCCs in animal models,3 with
Edn1 expressed in the mandibular but not the maxillary
prominence and Ednra expressed throughout the first
PA.6,7 Mutations in EDN1 have recently been reported in
individuals with auriculocondylar syndrome (ACS, a disor-
der affecting derivatives of the first and second PAs [MIM
615706]) or isolated question mark ears (MIM 612798).8
Mutations in PLCB4 (MIM 600810) and GNAI3 (MIM
139370), which encode signaling components down-
stream of EDNRA, have also been identified in ACS (MIM
602483 and 614669).9
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associated with abnormalities of the ears and eyelids.10
These defects are likely to result from abnormal develop-
ment of cranial NCCs or their derivatives. MFDs can occur
in an isolated form, as in Treacher Collins syndrome (MIM
154500), or can be part of a broader developmental defect,
as in Nager (MIM 154400) and Miller (MIM 263750) syn-
dromes. Here we delineate a syndrome that we have
named mandibulofacial dysostosis with alopecia (MFDA),
shared by four unrelated individuals in whom we identi-
fied two de novo missense substitutions in EDNRA, one
of which is recurrent. Functional evidence suggested that
both substitutions perturb normal endothelin signaling.Material and Methods
Whole-Exome Sequencing
Genetic analyses were performed in accordance with approved
institutional protocols (CPP Ile-de-France II and the Internal Re-
view Board at Cincinnati Children’s), and informed consent for
genetic testing was obtained from all participants.
For individual 3 whole-exome sequencing (WES), genomic DNA
was extracted from whole blood by standard methods. Library
construction was performed on dsDNA, sheared by sonication to
an average size of 200 bp, in an automated fashion on an IntegenX
Apollo324. After nine cycles of PCR amplification with the Clon-
tech Advantage II kit, 1 mg of genomic library was recovered for
exome enrichment by the NimbleGen EZ Exome V2 kit. Libraries
were sequenced on an Illumina HiSeq2500, generating approxi-
mately 30 million 100 bp paired end reads. Data analysis utilized
the Broad Institute’s Genome Analysis Toolkit (GATK).11 Reads
were aligned with the Illumina Chastity Filter with the Burrows
Wheeler Aligner (BWA).12 Variant sites were called with the
GATK Unified Genotyper module. Single-nucelotide variant calls
were filtered with the variant quality score recalibration
method.11 Golden Helix SNP and Variation Suite v.8.1.5 was
used to filter the variants. For individual 4 WES, protocols for li-
brary preparation, exome capture, sequencing (performed on an
Illumina HiSeq2500 sequencer), readmapping, and variant calling
and filtering were similar to that described previously.8
Cell Culture
MC3T3-E1 cells (ATCC) were cultured in MEM alpha (Invitrogen)
supplemented with 20% fetal bovine serum (Sigma) at 37C in a
HeraCell humidified incubator (Heraues) containing 5% CO2.
Whole-Mount In Situ Hybridization
Whole-mount in situ hybridization (ISH) was performed essen-
tially as previously described6 with a digoxigenin (DIG)-labeled
antisense cRNA riboprobe against Edn3. Embryos were photo-
graphed with an Olympus SZX12 microscope fitted with an
Olympus DP11 digital camera.
Wild-Type and Mutant EDNRA Overexpression
in MC3T3-E1 Cells
For in vitro analysis of wild-type and mutant EDNRA activity, an
expression vector (pCMV6-XL5) containing the full cDNA
sequence of human EDNRA transcript variant 1 (RefSeq accession
number NM_001957.1) (Origene) was used. To introduce the
p.Tyr129Phe substitution (which corresponds to a c.386A>T mu-520 The American Journal of Human Genetics 96, 519–531, April 2, 2tation, codon TAT to TTT), we used the QuickChange Lightning
Site-Directed Mutagenesis Kit (Agilent Technologies) according
to the manufacturer’s instructions for annealing and extension
times and cycle numbers. In brief, the mutant strand synthesis
was accomplished by PCR via mismatched primers containing
the c.386A>T mutation. Primer sequences were 50-tcttgcccttggag
accttatctttgtggtcattga-30; 50-tcaatgaccacaaagataaggtctccaagggcaa
ga-30. The PCR product wasDpnI treated to digest the template vec-
tor and transformed into XL10-Gold ultracompetent cells (Agilent
Technologies). The sequence of both the wild-type and mutant
vectors was verified by DNA sequencing. For transfection, X-trem-
eGENE 9 DNA transfection reagent (Roche) was used. 0.8 mg of
either the EDNRA wild-type or EDNRA p.Tyr129Phe-encoding
expression vector was transfected into MC3T3-E1 cells. Transfec-
tion complexes were made according to the manufacturer’s proto-
col, added to culture media, and removed 6 hr after transfection.
Cells were then starved overnight with MEM alpha supplemented
with 0.1% fetal bovine serum (Sigma-Aldrich). At 1 hr prior to cell
harvest, 10 mM BQ788 (Sigma-Aldrich), an EDNRB-specific antag-
onist, was added to themedia followed by 5 ml of ddH20 or 5 nM of
either EDN1 (Sigma-Aldrich) or EDN3 (Sigma-Aldrich).Quantitative Real-Time PCR
Transfected MC3T3-E1 cells were harvested 24 hr after transfec-
tion and RNAwas extracted with the RNeasy Micro Kit (QIAGEN).
cDNA was prepared from total RNA with the Quantitect cDNA
Synthesis Kit (QIAGEN). qRT-PCR was performed on 5 ng of
cDNA and the Quantitect SYBR Green PCR Kit (QIAGEN),
including Quantitect Assay primers for Dlx5 and Hand2
(QIAGEN). RT-PCR and data analysis was performed with a
MyiQ2 thermocycler (BioRad). Statistical analysis was conducted
with the statistical package in Excel.Zebrafish Morpholino and mRNA Injections
Zebrafish (Danio rerio) were raised and mated as described.13 Em-
bryos were injected at the 1- to 2-cell stage into the yolk sac
with 1 nl of solution containing MO, mRNA, or both via a micro-
injector. Phenotyping was carried out at 5 days post-fertilization
(dpf). Alcian blue staining was performed as described.14 Photo-
graphs were taken on a Nikon SMZ6 microscope. Measurements
were performed with ImageJ. Splice-blocking MO antisense oligo-
nucleotides against the two orthologs of EDNRA, ednraa (previ-
ously known as ednra2) and ednrab (previously known as ednra1),
were previously designed15 and obtained from GeneTools. MO se-
quences are as follows: ednraa 50-ATCAGACTTTTCTTTACCTGCT
TAA-30 and ednrab 50-AGTGGTGTGTTCACCTGTTTGAGGT-30.
Knockdown efficiency was assessed by RT-PCR across the exon-
intron boundary targeted by each MO (see Figure S8).Zebrafish Expression Constructs
Wild-type human EDNRA was amplified and cloned into the
pCS2þ expression vector as previously described.16 Site-directed
mutagenesis was performed to introduce the p.Tyr129Phe,
p.Ser167Ala, and p.Glu303Lys variants. Each mutant construct
was fully sequenced after mutagenesis to confirm presence of
the point mutation. Full-length wild-type human EDN1 and
EDN3 cDNA clones were obtained from the human ORF clone
collection (clone ID: IOH80822 and IOH57032, Life Technolo-
gies). ORF clones were fully sequenced and full-length cDNAs
were then transferred from pENTR to pCS2þ utilizing the Gateway
Cloning system (Life Technologies). Capped mRNAwas generated015
A Bfor all constructs utilizing the mMessage mMachine SP6 transcrip-
tion kit (Life Technologies).
Ednralacz/þ Expression Analysis
Ednralacz/þ mouse strain generation and X-gal staining procedure
have been previously described.17 Experiments in this report
were performed in accordance with institutional ethical
guidelines.C D
E F
G H
Figure 1. Phenotype of Mandibulofacial Dysostosis with Alope-
cia
Front and side views of facial features of individual 1 at age 1 year
8 months (A and B), of individual 2 at age 3 years 4 months (C and
D), of individual 3 at age 10 years (E and F), and of individual 4 at
age 13 years (G and H). Although individual 4 has a shaved head,
patches devoid of follicles can be observed.Results
Phenotype of Individuals with MFDA
Individuals 1–3 presented with a highly similar facial dys-
morphism, and individual 4, previously described as hav-
ing Johnson-McMillin syndrome18 (JMS [MIM 147770]),
displayed a milder phenotype (Figure 1 and Table 1). A
phenotypic description of individual 2 up to the age of 4
years has been previously published.19 Individuals 1–3 all
had micrognathia and cleft palate. Individuals 1 and 3
had limited jaw mobility and individual 3 had glossopto-
sis. Upper airway obstruction necessitated tracheostomy
for individuals 1 and 3. Individual 3 has remained trache-
ostomy dependent despite three mandibular distraction
osteogenesis surgeries (performed at 3 months, 2 years,
and 5.5 years of age). Individual 1 presented with irregular
placement of primary teeth in both upper and lower jaws.
Delayed eruption of primary teeth was previously noted in
individual 2,19 and at age 7, primary teeth were still present
with only 16 permanent tooth buds visible on radiographs,
indicating agenesis of multiple permanent teeth. Individ-
ual 3 did not have anomalies of tooth eruption or
morphology but had poor dental hygiene related to
mandibular ankylosis and dental crowding. Individuals
1–3 had an everted lower lip (see Figure S1 for pre-distrac-
tion pictures of individual 3), and all four individuals had a
similar short nose with a squared nasal tip. In individuals
1–3 the ears were small, cupped, and dysplastic with
ectopic tissue at the attachment of the helix to the scalp
(see Figure S1 for ectopic post-auricular tissue in individual
1); in individuals 1 and 3 this protuberance contained a
posteriorly facing pit. The ears of individual 4 were also
severely abnormal, with pre-auricular pits and tags.18
Conductive hearing loss has been treated with hearing
aids in individuals 1, 3, and 4. Individuals 1–3 had sparse
eyelashes and severe hypoplasia or aplasia of the eyelids
requiring reconstructive surgery, and individual 4 had a
lower eyelid coloboma. All four individuals had near-com-
plete alopecia, with less hair on the vertex relative to the
occipital region in individuals 1, 3, and 4. White hair was
present in individual 2.19 Although hyposmia was sus-
pected at a younger age in individual 2,19 it was not present
upon evaluation at 7 years of age. Growth and intellectual
development have been normal in all. Echocardiograms re-
vealed no defects in individuals 1, 2, and 4,18 although a
bicuspid aortic valve was detected in individual 3.
Computed tomography scans of individuals 1–3
confirmed a severe MFD (Figure 2). In all three, theThe American Journal of Human Genetics 96, 519–531, April 2, 2015 521
Table 1. Clinical Features of Individuals Studied in This Report
Individual 1 Individual 2 Individual 3 Individual 4
Previous publication not previously reported Zechi-Ceide et al.19 not previously reported Cushman et al.18
Diagnosis MFDA MFDA MFDA MFDA/JMS
Gender M M M F
MFD þ þ þ NA
Zygomatic arch (by CT scan) dysplastic dysplastic dysplastic NA
Mandible (by CT scan) dysplastic dysplastic dysplastic NA
Cleft palate þ þ þ 
Alopecia þ þ þ þ
Eyelid anomalies þ þ þ þ
Auricular dysmorphism þ þ þ þ
Hearing loss þ þ þ þ
Dental anomalies þ þ  
Other phenotypes megaureter white hairs bicuspid aortic valve 
EDNRA mutationa c.386A>T c.386A>T c.386A>T c.907G>A
Protein change p.Tyr129Phe p.Tyr129Phe p.Tyr129Phe p.Glu303Lys
Inheritance de novo (somatic mosaic) de novo de novo de novo (somatic mosaic)
Abbreviations are as follows: MFDA, mandibulofacial dysostosis with alopecia; JMS, Johnson-McMillin syndrome; F, female; M, male;þ, finding present;, finding
not present; NA, information not available.
aCo-ordinates refer to RefSeq transcript NM_001957.3.zygomatic process of each temporal bone was absent, the
maxillae were dysmorphic, and the malar bones were
thickened with grossly dysplastic ventral orbital margins.
The lateral margin of each orbit was essentially absent in
individual 3 and was hypoplastic in individuals 1 and 2.
The mandible was hypoplastic with reduced gonial angle
in individuals 1 and 2 and retro-positioned dental arcade
in individual 1. Note that the images of individual 3 in
Figure 2 are 6 months after his second mandibular distrac-
tion surgery. In individuals 1–3, the temporomandibular
joints were absent and the condyles were broad, flat, and
articulated with a proximal surface of the dysmorphic ma-
lar bones. In individuals 1–3 the coronal suture was dis-
placed anteriorly; the wings of the sphenoid were hypo-
plastic in individual 1. Individuals 1 and 2 displayed
deviation of the nasal cavities, and in individuals 1 and 3
the external auditory canals were narrow, the mastoids
were underpneumatized, the middle ear cavities were
small, and the ossicular chains were hypoplastic. Individ-
ual 3 had absent maxillary sinuses and hypoplastic ptery-
goid processes. Skeletal imaging was not available for indi-
vidual 4, but of note, Cushman et al.18 described
individual 4 as having depressions at the lateral aspects
of the eyes, consistent with underlying lateral orbital de-
fects as seen for individuals 1–3.
Genetic Analyses
Initial genetic analyses of the four MFDA-affected individ-
uals included chromosomal microarray analysis by Agilent522 The American Journal of Human Genetics 96, 519–531, April 2, 260k array-CGH for individuals 1 and 4, GeneChip SNP
array for individual 2,19 and SignatureSelect V2 BAC array
and Infinium Assay (Illumina HD Human610-quad Bead-
Chip platform) for individual 3. No likely pathogenic ab-
normalities were detected. Individuals 1, 2,19 and 3 also
had normal karyotypes.
Given the strong phenotypic similarities of individuals
1–3, we hypothesized that they could have mutations in
the same gene. Trio WES was therefore performed for indi-
vidual 3 and his parents (II:1, I:1, and I:2, respectively, in
Figure 3). WES was also done for individual 4 and her par-
ents (II:1, I:1, and I:2, respectively, in Figure 3), because her
milder phenotype suggested the possibility of another
locus. The absence of other affected family members for
all individuals suggested an autosomal-dominant mode
of inheritance with de novo mutations in the probands
as the most likely etiology.
WES of individual 3 and his parents was performed with
a mean depth of coverage for each sample of at least 89-
fold and with at least 97% of the exome covered 15-fold
or greater. We identified de novo rare variants predicted
to have a deleterious effect on protein function in ITGAE
(MIM 604682), WNT4 (MIM 603490), and EDNRA
(Table S1). The frameshift variant in ITGAE (RefSeq
NM_002208.4, c.2986delG [p.Glu996fs*24]) was consid-
ered unlikely to be pathogenic because a recurrent frame-
shift variant in this gene is listed in the Exome Variant
Server (EVS), and mice deficient in Itgae do not have
morphogenesis defects.20 Heterozygous missense WNT4015
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Figure 2. Craniofacial Skeletal Anomalies in Mandibulofacial
Dysostosis with Alopecia
Front and side views of 3D computed tomography (CT) scans of
individual 1 at age 6 months (A and B), of individual 2 at age
7 years (C and D), of individual 3 at age 2.5 years (E and F), and
of a normal individual at age 2.5 years (G and H).
Abbreviations are as follows: mal, malar bone; cond, condyle of
the mandible; ZPT, zygomatic process of the temporal bone. An
asterisk indicates structures that are dysmorphic relative to
normal.variants are associated with a human phenotype in females
(Mullerian aplasia and hyperandrogenism [MIM 158330]).
We confirmed the WNT4 variant (RefSeq NM_030761.4,
c.114dupA [p.Glu39fs*38]) in individual 3 by Sanger
sequencing but we found no coding variants in WNT4 in
the other three MFDA-positive individuals; the WNT4The Amvariant was therefore considered unlikely to contribute to
the phenotype of individual 3. Finally, the variant in
EDNRA (RefSeq NM_001957.3, c.386A>T [p.Tyr129Phe];
Figure S2) was confirmed de novo by Sanger sequencing
(Figures 3 and S3). Variants affecting Tyr129 of EDNRA
have not been reported in public SNP databases, and a tyro-
sine is conserved at this position in all sequenced verte-
brates, including lamprey.
Trio WES of individual 4 was performed with a mean
depth of coverage for each sample of at least 130-fold,
with 98% of the exome covered 15-fold or greater. Analysis
of the exome data under a recessive model yielded only
compound heterozygous missense variants in PAXIP1 (Ta-
ble S2). One of the affected PAXIP1 residues was not abso-
lutely conserved in sequenced mammals, and neither
affected residue fell within the known Pfam domains of
the protein; although we cannot exclude the influence of
these variants, PAXIP1 was not considered a strong candi-
date. Under a de novo model, the only variant predicted
to affect protein function and not previously reported in
public SNP databases (dbSNP138, EVS) or in-house exomes
was in EDNRA: c.907G>A (p.Glu303Lys) (RefSeq NM_
001957.3). Analysis of exome sequencing reads indicated
a 75%:25% bias in reference- versus variant-containing
reads for individual 4, with 100% reference-containing
reads for each parent (Figure S2). Sanger sequencing from
two independent blood samples from individual 4
(Figure S4) and an alternate pair of primers (data not
shown) indicated a similar bias in wild-type versus mutant
chromatogram peak height, and cloning of PCR products
yielded a 12:3 ratio of bacterial colonies harboring wild-
type:mutant sequences, suggesting that individual 4 was
somatic mosaic for the p.Glu303Lys EDNRA variant. The
residue Glu303 of EDNRA, as well as the equivalent amino
acid of EDNRB (Glu320), is highly conserved in vertebrates
and maps to the C-terminal portion of the third intra-
cellular loop2 (Figure 3). Deletion analysis has shown
that the equivalent region of the third intra-cellular loop
of EDNRB is required for EDN1-induced signaling.21
We subsequently performed Sanger sequencing of
EDNRA in individuals 1 and 2, and in both we identified
the same mutation found in individual 3 (RefSeq
NM_001957.3, c.386A>T [p.Tyr129Phe], Figure S3). The
mutations were confirmed as de novo in both individuals
1 and 2 (Figures 3 and S3). In individual 1, the mutation
appeared to be mosaic in DNA extracted from blood (the
same result was obtained from PCR products amplified
with two alternate pairs of primers) and from a buccal
swab (Figure S3 and data not shown). Mosaicism was
confirmed by cloning three PCR products from individual
1: two products contained the major allele of the SNP
rs6841473 (433 bp from the mutation) plus either the
mutant or wild-type allele at position 386 (cDNA
numbering), and the third product harbored the
rs6841473 minor allele and wild-type at position 386.
Given that a similar degree of mosaicism (judged by chro-
matogram peak intensity) was observed in two tissueerican Journal of Human Genetics 96, 519–531, April 2, 2015 523
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Figure 3. Pedigrees and EDNRA Muta-
tions Identified for Individuals 1–4
(A) Pedigrees of individuals 1–4. Arrows
indicate probands. Presence of a mutant
allele is indicated by a minus sign.
(B) Schematic of the EDNRA protein, with
red dots indicating the positions of the
MFDA substitutions (listed below the
schema). Protein domains not drawn to
scale. Abbreviations are as follows: ECL,
extra-cellular loop; ICL, intra-cellular loop.sources, the mutation is likely to have arisen within the
first few divisions after conception. The absence of visible
skin pigmentation anomalies in individual 1, which might
occur with somatic mutations that arise later in develop-
ment, is consistent with this (assuming that an EDNRA
mutation could indeed affect pigmentation). Paternity
was confirmed in individuals 1 and 2 by analysis of more
than ten unlinked and informative microsatellite markers.
In Vitro Functional Analysis of the EDNRA
p.Tyr129Phe Variant
Tyr129, located within the second transmembrane domain
of EDNRA (Figure 3), has been shown to be critical for the
selective affinity of endothelin ligand subtype: mutagen-
esis of tyrosine to several different amino acids, including
phenylalanine (the recurrent MFDA substitution), results
in an ~100-fold increase in affinity for EDN3, without
change in affinity for EDN1.4,5,22 EDN3 is expressed in
the first PA in humans,23 chick,24 and mice (Figure S5
and microarray data from the FaceBase Consortium,25 as
displayed in the UCSC Genome Browser), raising the pos-
sibility that in MFDA, EDN3 present in the first PA binds
to and alters signaling downstream of mutant EDNRA. To
better understand the effect of the p.Tyr129Phe variant
on EDNRA function, we generated an EDNRA expression
construct encoding the p.Tyr129Phe variant and addressed
whether the mutated EDNRA could still activate down-
stream effectors of endothelin signaling, in vitro, in
response to EDN1 and EDN3. Cells from the mouse pre-
osteoblastic cell line MC3T3-E1 were transfected with
either the EDNRA wild-type or EDNRA p.Tyr129Phe-en-
coding expression constructs and then starved overnight.
After 24 hr, cells were stimulated with either EDN1 or524 The American Journal of Human Genetics 96, 519–531, April 2, 2015EDN3. To limit our analysis to the ef-
fects resulting from EDNRA signaling,
we also included BQ788, an EDNRB-
specific antagonist. One hour later,
cells were collected and RNA was iso-
lated. To assess EDNRA signaling ac-
tivity, we measured the expression
levels of two downstream markers of
the EDN1-EDNRA pathway, Dlx5
and Hand2, by qRT-PCR. Both EDN1
and EDN3 resulted in a significant in-
crease in Dlx5 and Hand2 mRNAlevels in cells in which the wild-type EDNRA expression
construct had been introduced (Figure 4). In contrast,
neither EDN1 nor EDN3 resulted in significant increases
inDlx5 and Hand2mRNA levels in cells expressing EDNRA
p.Tyr129Phe (Figure 4). When the above experiments were
repeated in the absence of BQ788, upregulation of both
Dlx5 and Hand2 was less robust or no longer significantly
changed, suggesting a negative influence of EDNRB
signaling on expression of these genes in this system
(Figure S6). These data indicate that, in vitro, EDNRA is
able to respond to both EDN1 and EDN3 and that the
p.Tyr129Phe substitution disrupts this response.
Functional Analysis of the EDNRAVariants in
Zebrafish
We utilized zebrafish to provide further evidence for the
pathogenicity of the EDNRA variants identified in MFDA-
affected individuals. First, we injected increasing doses
(100, 150, and 300 pg) of mRNAs encoding human wild-
type or mutant (p.Tyr129Phe, p.Glu303Lys) EDNRA into
1- to 2-cell stage embryos. At 5 days post-fertilization
(dpf), cartilage structures of zebrafish embryos were visual-
ized by whole-mount alcian blue staining. Misexpressing
embryos (EDNRA wild-type, n ¼ 163; p.Tyr129Phe, n ¼
145; p.Glu303Lys, n ¼ 161) were indistinguishable from
uninjected embryos (n ¼ 157) from the same clutch, and
no quantifiable craniofacial defects were detected in em-
bryos injected with either wild-type or mutant EDNRA
mRNAs (Figures 5C and S7 and data not shown for
p.Glu303Lys). To exclude the possibility that the absence
of phenotype was due to the degradation of the injected
human RNAs, total RNA from injected embryos was ex-
tracted at 50 hr post-fertilization (hpf), a time point well
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Figure 4. Response of EDNRA and EDNRA p.Tyr129Phe to EDN1
and EDN3 In Vitro
After transfection of MC3T3-E1 cells with an expression vector en-
coding either wild-type EDNRA or EDNRA p.Tyr129Phe, cells were
treated with vehicle, EDN1, or EDN3 and then RNA collected for
qRT-PCR analysis of Dlx5 and Hand2 expression. All treatments
were performed in the presence of the EDNRB antagonist BQ788
to exclude expression changes due to EDNRB signaling. Each con-
dition represents an average of results from three separate transfec-
tion experiments. Error bars represent standard error of the mean.
Results are normalized to vehicle within each expression assay
(Dlx5 or Hand2). *p < 0.05; **p < 0.01; ***p < 0.001; n.s., not sta-
tistically significant (p> 0.05). Statistical test was a two-tailed t test
(assuming equal variance).past the patterning of NCC mesenchyme in the PAs. We
confirmed the presence of the p.Tyr129Phe-encoding hu-
manmessage by RT-PCR by utilizing primers to specifically
amplify human EDNRA (Figure S7). The absence of pheno-
type upon misexpression of mutant EDNRAs argues
against a dominant-negative effect.
We next tested the possibility that the variants act as
loss-of-function alleles. EDNRA has two known orthologs
in zebrafish: Ednraa (73% identity to human EDNRA pro-
tein) and Ednrab (72% identity). 1- to 2-cell stage zebrafish
embryos were injected with MOs previously shown to
target ednraa and ednrab.15 To quantify the phenotype,
we measured the length of Meckel’s cartilage in controls
and MO-injected embryos. MO knockdown of both
EDNRA orthologs in zebrafish recapitulated the reported
loss of function of edn1 (suckermutant)26 with either com-
plete absence or reduction of Meckel’s cartilage length (Fig-
ures 5B, 5E, and 5G); besides the jaw phenotype, no appre-
ciable gross abnormalities were observed (Figures S8A and
8B). We observed a significant rescue of the morphant
phenotype by co-injecting both MOs with mRNAs encod-
ing wild-type human EDNRA (p < 0.005, Figure 5G) or the
p.Tyr129Phe variant; the latter rescued significantly betterThe Amthan wild-type EDNRA (p < 0.005 between wild-type and
mutant rescue, Figure 5G), suggesting that p.Tyr129Phe
is not a loss-of-function variant in this assay. By contrast,
the p.Glu303Lys variant did not rescue the phenotype
(non-significant compared to MOs alone, Figure 5G).
Next, we sought to determine whether p.Tyr129Phe and
p.Glu303Lys are capable of altering the response of the re-
ceptor to the human ligands EDN1 and EDN3 in zebrafish
embryos by co-injecting wild-type or mutant EDNRA
mRNAs with either human EDN1 or EDN3 transcripts.
Co-injections of mRNAs encoding ligand and receptor
were toxic at high doses; we therefore injected suboptimal
doses (5 pg of each mRNA) to decrease the penetrance of
the phenotype and to give the dynamic range necessary
to detect possible interaction between ligands and wild-
type or mutant receptors. Co-injection of various ligand-
receptor combinations resulted in a range of rostral hypo-
plasia phenotypes of variable penetrance, which included
a reduction of the volume of the telencephalon bringing
the eyes closer together, frequent cyclopia, eye anteversion
(rotation inward), and complex cartilage defects probably
secondary to the forebrain and eye defects, including
absence of the ethmoid plate and ventral displacement of
the trabecular, Meckel’s, and ceratohyal (Figures 6D–6I).
These phenotypes were found in approximately 5% of
the wild-type EDNRA and EDN1 mRNA co-injected em-
bryos, whereas no appreciable phenotype was observed
in embryos injected with wild-type EDNRA and EDN3
mRNAs (Figures 6J and 6K). Notably, the percentage of
affected embryos increased to 20% upon co-injection of
EDN1 mRNA with either EDNRA p.Tyr129Phe- or
p.Glu303Lys-encoding mRNAs (p < 0.001 compared to
EDN1 and wild-type EDNRA; Figure 6K), whereas 10% or
15% of the embryos co-injected with EDN3 mRNA and
EDNRA p.Tyr129Phe- or p.Glu303Lys-encoding mRNAs,
respectively, displayed rostral hypoplasia phenotypes (p
< 0.001 compared to EDN3 and wild-type EDNRA;
Figure 6J). Given that Glu303 maps to an intracellular
loop of EDNRA, the molecular mechanism underlying
the EDN3-mediated effect on p.Glu303Lys remains un-
clear, but is probably different to that of p.Tyr129Phe.
The rostral hypoplasia phenotypes were unlikely to be
driven by overall developmental delay; misexpressing em-
bryos had no apparent pathology in other internal organs,
such as the heart or the swim bladder, and their body
length was indistinguishable from that of control embryos
from the same clutch (Figure S8F; EDN1 and wild-type
EDNRA co-injected embryo shown as representative). We
note that the forebrain and eye phenotypes reported above
are not representative of the phenotypes in individuals
with MFDA, nor of other human or animal models of per-
turbed endothelin signaling. These phenotypes are prob-
ably caused by misexpression of endothelin ligand-recep-
tor combinations in the developing neuroepithelium.
Despite being the product of ectopic expression, these phe-
notypes do nevertheless provide a readout for wild-type
versus mutant EDNRA protein activity in response toerican Journal of Human Genetics 96, 519–531, April 2, 2015 525
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Figure 5. EDNRA p.Tyr129Phe but Not p.Glu303Lys Rescues Ventral Pharyngeal Arch Defects Caused by ednra Knockdown in Zebra-
fish
(A, B, D, and E) Ventral and lateral views of uninjected controls (A and D) and embryos injected with ednraa and ednrab morpholinos
(MOs) (B and E) and stained with alcian blue. Meckel’s cartilage is indicated by a bar in (D).
(C) Injection of mRNA encoding human EDNRA p.Tyr129Phe (150 pg) did not result in a discernable phenotype.
(F) Injection of mRNA encodingwild-type (WT) human EDNRA partially rescues the ventral cartilage defect induced byMO knock-down
of the zebrafish ednra orthologs.
(G) Bar graphs showing measurements of the length of Meckel’s cartilage. The first column represents uninjected embryos. For each co-
injection, 100 pg of mRNA was injected. Meckel’s cartilage reduction is rescued significantly by both EDNRAWT and EDNRA p.Tyr129-
Phe-encodingmRNAs but not by EDNRA p.Glu303Lys-encodingmRNA. Statistical significance (Student’s t test) is denoted by p values or
n.s. (not significant) on the bar graphs. Error bars represent standard error of the mean. Data are from three independent experiments.ligand. In the above assays, it appears that the p.Tyr129Phe
and p.Glu303Lys variants have the capacity to perturb
EDNRA activity in an endothelin ligand-dependent
manner.526 The American Journal of Human Genetics 96, 519–531, April 2, 2In addition to p.Tyr129Phe, Krystek et al. tested the
selectivity of endothelin ligand binding to another variant,
p.Ser167Ala, because as for Tyr129, Ser167 is predicted to
fall at the ligand binding cavity of EDNRA, and differs015
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Figure 6. Co-expression of Endothelins
and EDNRA Variants in Zebrafish
(A–C) Embryos injected with 5 pg of EDN1
mRNA.
(D–F) Embryos co-injected with 5 pg each
of EDN1 and wild-type (WT) EDNRA
mRNAs.
(G–I) Co-injection of 5 pg each of mRNAs
encoding EDNRA p.Glu303Lys and EDN1.
All embryos are shown at 5 dpf. Abbrevia-
tions are as follows: mc, Meckel’s; pq, pala-
toquadrate; ch, ceratohyal; tr, trabecula.
(A, D, and G) Brightfield images.
(B, E, and H) Lateral views of alcian blue-
stained embryos.
(C, F, and I) Ventral views of alcian blue-
stained embryos.
Co-injected embryos in (D)–(I) exhibit a
pronounced rostral hypoplasia phenotype
including severe eye separation defects
and loss of the ethmoid plate (ep; asterisk
when reduced or absent) with relative pres-
ervation and downward displacement of
the facial cartilages.
(J and K) Percentage of embryos with
rostral hypoplasia is shown for co-injec-
tions with EDN3 (J) and EDN1 (K) mRNAs.
The first column of each graph represents
uninjected embryos. Error bars represent
the 95% confidence interval of the mean.
Fisher’s exact test was performed and
p values are as follows: #p < 0.001 versus
EDN3 and WT, %p < 0.001 versus EDN1
and WT, $p < 0.001 versus EDN3 and
WT; n.s. is compared to respective EDN-
alone injection.between EDNRA and EDNRB. However, unlike p.Tyr129-
Phe, p.Ser167Ala appeared to display decreased binding af-
finity for EDN3.4 We found that mRNA encoding the
p.Ser167Ala variant significantly rescued the ednra mor-
phant phenotype in zebrafish (p ¼ 9.7 3 1010;
Figure S8D), suggesting that this variant does not perturb
normal endothelin signaling. To test further the possibility
that direct binding of EDN3 to EDNRA p.Tyr129Phe can
lead to dysregulation of downstream signaling, we gener-
ated mRNA encoding the double-mutant EDNRA
p.Tyr129Phe/p.Ser167Ala and co-injected with EDN3
mRNA. We hypothesized that binding of EDN3 to
p.Tyr129Phe might be inhibited by the presence of
p.Ser167Ala on the same receptor molecule, and the dou-The American Journal of Humable mutant might therefore reduce
the penetrance of the phenotype
observed upon co-injection of EDN3
mRNA and mRNA encoding the sin-
gle-mutant EDNRA p.Tyr129Phe.
Indeed, we observed that co-injection
of mRNAs encoding EDN3 and
EDNRA p.Tyr129Phe/p.Ser167Ala led
to a significant reduction in the
percentage of affected embryos
compared to co-injection of mRNAsencoding EDN3 and EDNRA p.Tyr129Phe (p < 0.001,
Figure 6J). Upon co-injection of mRNAs encoding EDN1
and the double-mutant EDNRA p.Tyr129Phe/p.Ser167Ala,
the percentage of affected embryos was not significantly
different from that observed upon co-injection of mRNAs
encoding EDN1 and the single p.Tyr129Phe mutant
(Figure 6K), suggesting that although p.Ser167Ala abro-
gates the effects of EDN3 on p.Tyr129Phe, p.Ser167Ala
has no effect on the consequences of EDN1-mediated
signaling via p.Tyr129Phe.
Ednralacz Expression
All MFDA-affected individuals have alopecia, yet very little
is known about the normal role of EDNRA in hair folliclen Genetics 96, 519–531, April 2, 2015 527
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Figure 7. Ednralacz/þ Expression in
Mouse Embryos
(A and B) Ednraþ/þ (A) and Ednralacz/þ (B)
whole-mount E15.5 embryos stained with
X-gal. White arrows indicate eyelid and
pinna expression of Ednralacz. The inset in
(B) is a magnified view of an Ednralacz/þ
hair follicle.
(C) Cryosection of whole-mount X-gal-
stained E13.5 Ednralacz/þ embryo.
(D and E) Ednraþ/þ (D) and Ednralacz/þ (E)
postnatal day (P) 0 X-gal-stained cryosec-
tions of vibrissal follicles. Abbreviations
are as follows: dp, dermal papilla; m, ma-
trix; vf, vibrissal follicle.development. By utilizing a mouse line in which lacz is
knocked-in to the Ednra locus,17 we observed strong
expression of Ednralacz in hair follicles at multiple stages
of follicular development (Figure 7). Ednralacz expression
was also observed in other tissues that are strongly affected
in MFDA: in the developing eyelids and in the pinnae,
particularly the dorsal and ventral regions of the pinnae
that fuse with the scalp (Figure 7).Discussion
Here we have described a disorder characterized by MFD
and alopecia that is caused by de novo missense substitu-
tions in EDNRA. We identified mutations in four unrelated
simplex cases. In three of the four individuals, Tyr129 is
substituted; this amino acid is the key determinant of pref-
erential affinity of EDNRA for endothelin ligand subtype.4,5
The recurrent MFDA substitution p.Tyr129Phe had previ-
ously been shown to increase affinity of EDNRA for EDN3,
its non-preferred ligand. Furthermore, the importance of
Tyr129 in ligand selectivity has been used as the basis for
rational design of EDNRA-specific antagonists.27
The consequences of the MFDA variants on signaling
(and by extension, on phenotype) might differ depending
on the regional composition of endothelin ligands and
downstream signaling components within the PAs. Ednra528 The American Journal of Human Genetics 96, 519–531, April 2, 2015is expressed by all cranial NCCs soon
after they emerge from the neural
tube,6,7 whereas Edn1 expression is
restricted to the mandibular portion
of the first PA and more caudal
arches.6,7,28,29 A homeotic transfor-
mation of themandible into amaxilla
has been reported in Edn1, Ednra, or
Dlx5 and Dlx6 knock-out mice.3 The
mandibular alterations in ACS are
thought to represent a similar trans-
formation.9,30 The inverse transfor-
mation, consisting of the modifica-
tion of the upper jaw into a
mandible-like structure, has beenobserved upon injection of human EDN1 into the PAs of
zebrafish31 and knock-in of the Edn1 cDNA into the Ednra
locus in mice (EdnraEdn1/þ).7 In the maxillary prominence
of EdnraEdn1/þ embryos, ectopic Edn1 expression resulted
in upregulation of target genes normally restricted to the
mandibular prominence. MFDA-affected individuals 1–3
displayed increased symmetry across the jaw joint, as
had been observed in EdnraEdn1/þ mouse embryos, along
with absence of the zygomatic process of the temporal
bone and enlargement of the malar bone, suggesting a par-
tial homeotic transformation of the upper jaw into a
mandible-like structure (Figure 2). MFDA-affected individ-
uals and EdnraEdn1/þ embryos also share eyelid hypoplasia.
These phenotypic comparisons support the hypothesis
that an ectopic and/or constitutive activation of EDNRA
in the developing first PA (particularly the regions giving
rise to the upper jaw) underlies the MFDA phenotype.
Given the increased affinity of EDN3 for the p.Tyr129Phe
variant, this hypothesis would imply that EDN3 present
in the maxillary prominence might positively affect
signaling via the mutant EDNRA, leading to ectopic activa-
tion. In zebrafish, co-misexpression of EDN3 and mutant
EDNRA resulted in a higher frequency of rostral neural
tube phenotypes than co-misexpression of EDN3 and
wild-type EDNRA. This phenotypic readout, although not
biologically related to the MFDA phenotype, supports the
possibility that EDN3 can elicit aberrant signaling
consequences via mutant EDNRA in some contexts.
Another argument against the MFDA variants being
entirely loss of function is the phenotype of ACS and iso-
lated question mark ears, both of which result from loss-
of-function or dominant-negative variants in EDN1,
PLCB4, and GNAI3, encoding components of the EDNRA
pathway.8,32,33 In ACS the lower jaw is typically extremely
hypoplastic and the upper jaw is essentially normal. Simi-
larly, the lower jaw of Ednra-null mice is more severely
affected than the upper jaw.6,34 However, we cannot
exclude the possibility that a loss of normal EDNRA
signaling function contributes in part to the MFDA pheno-
type. Our analysis of gene expression downstream of wild-
type EDNRA or EDNRA p.Tyr129Phe in cultured cells indi-
cated that although the wild-type receptor was able to
respond to EDN1 and EDN3, neither EDN1 nor EDN3 ap-
peared to induce Dlx5 or Hand2 expression via mutant
EDNRA. Given the above hypothesis that the MFDA
phenotype might be due to an EDN3-mediated gain of
function of EDNRA in the upper jaw, this in vitro result
was surprising. However, published in vitro studies have
shown that a p.Tyr129Ala EDNRA variant had reduced
function (decreased levels of phosphoinositide turnover
and extracellular acidification) when stimulated with
EDN1, compared to the wild-type receptor.35 On the other
hand, EDNRA p.Tyr129Phe was able to rescue the pheno-
type of zebrafish in which the endogenous ednra genes
were knocked down. This finding argues that at least
some wild-type activity is retained by the mutant receptor.
It is plausible that although this activity is sufficient to
rescue the effect of theMOs, inMC3T3-E1 cells the compo-
sition of G proteins and other downstream components
necessary for Dlx5/Hand2 induction might not be optimal,
such that in our in vitro assays a partial loss of function of
the mutant receptor was exacerbated. One caveat to the
cell culture studies is that the response of the mutant re-
ceptor to endothelins in MC3T3-E1 cells might simply
not be representative of the response that occurs in
pharyngeal arch cells in vivo. The effects of reduced
signaling capacity of the mutant receptor might be
restricted to certain regions within the PAs. Specifically,
reduced signaling by EDN1 via the mutant receptor could
explain, in part, the micrognathia observed in MFDA-
affected individuals 1–3. Although Edn3 does appear to
be expressed in the mandibular prominence, it is less likely
that the micrognathia is due to increased mutant EDNRA
signaling induced by EDN1/EDN3, because micrognathia
is not observed in EdnraEdn1/þ embryos.7
AllMFDA-affected individualspresentedwithalopecia.To
our knowledge a role for endothelin signaling in hair devel-
opment has not been previously established. EdnraEdn1/þ
mice die perinatally, preventing analysis of postnatal hair
development. However, it has been demonstrated that the
expression of Ednra and Edn2 is regulated by nuclear factor
I/B (NFIB) in hair follicle stem cells,36 and transcriptomic
analysis suggested high relative expression of EDNRA and
EDN3 in thedermalpapilla, amesenchymal signaling centerThe Amof the hair follicle.37 In a mouse line driving lacz expression
from the Ednra locus, we observed strong expression during
hair follicle development. Of note, alopecia is observed in
mice in which Dlx3 (a target gene of Ednra signaling in the
mandible) is conditionally deleted in skin.38 Our observa-
tion of Ednralacz expression in the developing eyelids and
pinnae is also consistent with a primary defect in these tis-
sues in MFDA and EdnraEdn1/þmice. Finally, given the pres-
ence of tooth agenesis in individual 2, it isworthnoting that
Ednralacz expression has been previously demonstrated in
condensing mesenchyme adjacent to the dental lamina.17
Eyelid and tooth defects have not been reported in Ednra-
nullmice, suggesting that EDNRA does not play an essential
role in those tissues. However, the presence of Ednralacz
expression at those sites is consistent with the hypothesis
that the MFDA phenotypes in those tissues are caused by a
gain of function of EDNRA signaling. Eyelid defects are pre-
sent in EdnraEdn1/þ mice, emphasizing that EDNRA over-
activation within its endogenous expression domain can
lead to phenotypes not observed in the loss-of-function
situation.
Zechi-Ceide et al.19 suggested that individual 2 might
represent a severe form of JMS, a condition characterized
by alopecia, hyposomia or anosmia, hypogonadotropic
hypogonadism, hearing loss, and ear malformations. Of
published JMS-affected individuals, we considered that in-
dividual 4 in the present report, originally described by
Cushman et al.,18 was the most phenotypically similar to
MFDA-affected individuals 1–3. Despite confirmation
here that the individual in Cushman et al. has an EDNRA
mutation, we remain cautious about the possibility that
other JMS-affected individuals in the literature also have
EDNRA mutations. Those JMS-affected individuals do not
appear to have eyelid or orbital anomalies, nor auricular
anomalies of the type observed in our EDNRA-mutated in-
dividuals.39–43 Given the phenotypic similarities between
individual 4 with the p.Glu303Lys variant and individuals
1–3, we speculate that p.Glu303Lys might also be gain of
function, although perhaps ligand independent, given
that it falls in an intra-cellular loop of the protein. How-
ever, EDNRA harboring p.Glu303Lys failed to rescue the
ednra MO phenotype in zebrafish, suggesting that it is
loss of function in that assay. Based on the phenotypes
of the affected individuals, it is difficult to know whether
p.Tyr129Phe and p.Glu303Lys are truly equivalent in
signaling output, because the latter was a somatic mosaic
mutation and was associated with a milder phenotype.
In the ligand-receptor co-misexpression assays, the combi-
nation of either ligand plus p.Glu303Lys gave a higher
frequency of rostral hypoplasia phenotypes than ligand
plus wild-type receptor. One could speculate that this
intra-cellular mutation changes the conformation of the
receptor molecule in such a way that the ligands bind
and/or activate the receptor differently to the wild-type
receptor.
In conclusion,we report four unrelated individualswith a
unique combination of MFD and alopecia, ascribed toerican Journal of Human Genetics 96, 519–531, April 2, 2015 529
mutations in EDNRA. The recurrent tyrosine-to-phenylala-
nine substitution at position 129 leads to loss of selec-
tive affinity of EDNRA for EDN1. A tyrosine at position
129 is conserved in EdnrA in lamprey, an agnathan
vertebrate that within the PAs displays dorso-ventral re-
striction of expression of some genes known to be
downstream of EDN1-EDNRA in gnathostomes.44,45 Of
note, a phenylalanine is found at this position in the
Ednr-like gene of amphioxus, a non-vertebrate chor-
date.2 We speculate that acquisition of a tyrosine at po-
sition 129 in an ancestral EDNR gene was a key event in
the evolution of selective affinity among endothelin
substrates, and in combination with polarized EDN1
expression, might have been important for the evolu-
tion of mandibular specification within the first PA in
vertebrates.
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